Everest Organics develops new API to treat Covid-19

12 Oct 2021 Evaluate

Everest Organics has unveiled the successful development of an anti-viral API 'MOLNUPIRAVIR' an additional COVID -19 treatment drug that is being developed at Lab Scale for the first-line treatment of COVID-19 in adults patients with mild to moderate symptoms. Everest is planning and preparing to be an active player in viral segment in the upcoming future.

Everest Organics is a fast growing API and Bulk drug manufacturing company with world class facility and it is committed to manufacturing excellent quality products and customer service.

Everest Organics Share Price

280.10 -26.15 (-8.54%)
09-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1807.60
Dr. Reddys Lab 1286.40
Cipla 1325.15
Zydus Lifesciences 908.65
Lupin 2301.70
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×